INTEGRA LIFESCIENCES HOLDING (IART) Fundamental Analysis & Valuation

NASDAQ:IART • US4579852082

Current stock price

11.14 USD
+0.3 (+2.77%)
At close:
11.14 USD
0 (0%)
After Hours:

This IART fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. IART Profitability Analysis

1.1 Basic Checks

  • IART had positive earnings in the past year.
  • In the past year IART had a positive cash flow from operations.
  • In multiple years IART reported negative net income over the last 5 years.
  • Each year in the past 5 years IART had a positive operating cash flow.
IART Yearly Net Income VS EBIT VS OCF VS FCFIART Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M -400M

1.2 Ratios

  • IART has a Return On Assets (-14.34%) which is in line with its industry peers.
  • With a Return On Equity value of -49.50%, IART perfoms like the industry average, outperforming 49.47% of the companies in the same industry.
  • IART's Return On Invested Capital of 4.34% is fine compared to the rest of the industry. IART outperforms 73.94% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for IART is below the industry average of 9.15%.
Industry RankSector Rank
ROA -14.34%
ROE -49.5%
ROIC 4.34%
ROA(3y)-4.24%
ROA(5y)-0.72%
ROE(3y)-15.23%
ROE(5y)-5.13%
ROIC(3y)5.05%
ROIC(5y)5.6%
IART Yearly ROA, ROE, ROICIART Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 -20 -30 -40

1.3 Margins

  • Looking at the Operating Margin, with a value of 10.58%, IART is in the better half of the industry, outperforming 79.26% of the companies in the same industry.
  • IART's Operating Margin has declined in the last couple of years.
  • The Gross Margin of IART (56.62%) is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of IART has declined.
Industry RankSector Rank
OM 10.58%
PM (TTM) N/A
GM 56.62%
OM growth 3Y-17.47%
OM growth 5Y-7.89%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.52%
GM growth 5Y-2.59%
IART Yearly Profit, Operating, Gross MarginsIART Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. IART Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so IART is destroying value.
  • The number of shares outstanding for IART has been increased compared to 1 year ago.
  • The number of shares outstanding for IART has been reduced compared to 5 years ago.
  • Compared to 1 year ago, IART has a worse debt to assets ratio.
IART Yearly Shares OutstandingIART Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
IART Yearly Total Debt VS Total AssetsIART Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.2 Solvency

  • IART has an Altman-Z score of 1.21. This is a bad value and indicates that IART is not financially healthy and even has some risk of bankruptcy.
  • IART's Altman-Z score of 1.21 is in line compared to the rest of the industry. IART outperforms 50.53% of its industry peers.
  • IART has a Debt/Equity ratio of 1.66. This is a high value indicating a heavy dependency on external financing.
  • IART has a worse Debt to Equity ratio (1.66) than 82.45% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.66
Debt/FCF N/A
Altman-Z 1.21
ROIC/WACC0.71
WACC6.15%
IART Yearly LT Debt VS Equity VS FCFIART Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 2.54 indicates that IART has no problem at all paying its short term obligations.
  • IART has a Current ratio of 2.54. This is comparable to the rest of the industry: IART outperforms 47.34% of its industry peers.
  • IART has a Quick Ratio of 1.46. This is a normal value and indicates that IART is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.46, IART is doing worse than 63.83% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.54
Quick Ratio 1.46
IART Yearly Current Assets VS Current LiabilitesIART Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. IART Growth Analysis

3.1 Past

  • IART shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.89%.
  • Measured over the past years, IART shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.86% on average per year.
  • Looking at the last year, IART shows a small growth in Revenue. The Revenue has grown by 1.53% in the last year.
  • Measured over the past years, IART shows a small growth in Revenue. The Revenue has been growing by 3.57% on average per year.
EPS 1Y (TTM)-12.89%
EPS 3Y-12.69%
EPS 5Y-1.86%
EPS Q2Q%-14.43%
Revenue 1Y (TTM)1.53%
Revenue growth 3Y1.63%
Revenue growth 5Y3.57%
Sales Q2Q%-1.74%

3.2 Future

  • Based on estimates for the next years, IART will show a small growth in Earnings Per Share. The EPS will grow by 7.61% on average per year.
  • Based on estimates for the next years, IART will show a small growth in Revenue. The Revenue will grow by 3.00% on average per year.
EPS Next Y7.41%
EPS Next 2Y8.27%
EPS Next 3Y7.61%
EPS Next 5YN/A
Revenue Next Year2.65%
Revenue Next 2Y3.02%
Revenue Next 3Y3%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
IART Yearly Revenue VS EstimatesIART Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 500M 1B 1.5B
IART Yearly EPS VS EstimatesIART Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

7

4. IART Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 5.00, the valuation of IART can be described as very cheap.
  • Based on the Price/Earnings ratio, IART is valued cheaply inside the industry as 97.87% of the companies are valued more expensively.
  • IART's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.87.
  • IART is valuated cheaply with a Price/Forward Earnings ratio of 4.65.
  • Based on the Price/Forward Earnings ratio, IART is valued cheaply inside the industry as 98.94% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 38.51, IART is valued rather cheaply.
Industry RankSector Rank
PE 5
Fwd PE 4.65
IART Price Earnings VS Forward Price EarningsIART Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 95.21% of the companies in the same industry are more expensive than IART, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 7.42
IART Per share dataIART EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

  • IART's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.67
PEG (5Y)N/A
EPS Next 2Y8.27%
EPS Next 3Y7.61%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IART Dividend Analysis

5.1 Amount

  • No dividends for IART!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IART Fundamentals: All Metrics, Ratios and Statistics

INTEGRA LIFESCIENCES HOLDING

NASDAQ:IART (4/17/2026, 8:19:47 PM)

After market: 11.14 0 (0%)

11.14

+0.3 (+2.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-26
Earnings (Next)04-29
Inst Owners97.9%
Inst Owner Change-0.02%
Ins Owners2.97%
Ins Owner Change-0.1%
Market Cap867.03M
Revenue(TTM)1.64B
Net Income(TTM)-516.47M
Analysts55
Price Target16.66 (49.55%)
Short Float %13.23%
Short Ratio10.95
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.69%
Min EPS beat(2)1.67%
Max EPS beat(2)21.7%
EPS beat(4)3
Avg EPS beat(4)4.71%
Min EPS beat(4)-6.76%
Max EPS beat(4)21.7%
EPS beat(8)5
Avg EPS beat(8)3.77%
EPS beat(12)6
Avg EPS beat(12)3.61%
EPS beat(16)9
Avg EPS beat(16)4.3%
Revenue beat(2)0
Avg Revenue beat(2)-2.8%
Min Revenue beat(2)-4.85%
Max Revenue beat(2)-0.75%
Revenue beat(4)1
Avg Revenue beat(4)-1.01%
Min Revenue beat(4)-4.85%
Max Revenue beat(4)3.14%
Revenue beat(8)1
Avg Revenue beat(8)-1.01%
Revenue beat(12)2
Avg Revenue beat(12)-1.1%
Revenue beat(16)3
Avg Revenue beat(16)-0.92%
PT rev (1m)5.38%
PT rev (3m)5.38%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-16.36%
EPS NY rev (1m)0.37%
EPS NY rev (3m)-0.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.62%
Revenue NY rev (1m)-0.06%
Revenue NY rev (3m)-0.06%
Valuation
Industry RankSector Rank
PE 5
Fwd PE 4.65
P/S 0.53
P/FCF N/A
P/OCF 17.23
P/B 0.83
P/tB N/A
EV/EBITDA 7.42
EPS(TTM)2.23
EY20.02%
EPS(NY)2.4
Fwd EY21.5%
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)0.65
OCFY5.8%
SpS20.98
BVpS13.39
TBVpS-9.06
PEG (NY)0.67
PEG (5Y)N/A
Graham Number25.918 (132.66%)
Profitability
Industry RankSector Rank
ROA -14.34%
ROE -49.5%
ROCE 5.5%
ROIC 4.34%
ROICexc 4.74%
ROICexgc 12.06%
OM 10.58%
PM (TTM) N/A
GM 56.62%
FCFM N/A
ROA(3y)-4.24%
ROA(5y)-0.72%
ROE(3y)-15.23%
ROE(5y)-5.13%
ROIC(3y)5.05%
ROIC(5y)5.6%
ROICexc(3y)5.53%
ROICexc(5y)6.31%
ROICexgc(3y)19.84%
ROICexgc(5y)22.5%
ROCE(3y)6.39%
ROCE(5y)7.09%
ROICexgc growth 3Y-20.99%
ROICexgc growth 5Y-10.51%
ROICexc growth 3Y-13.95%
ROICexc growth 5Y-5.53%
OM growth 3Y-17.47%
OM growth 5Y-7.89%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.52%
GM growth 5Y-2.59%
F-Score4
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 1.66
Debt/FCF N/A
Debt/EBITDA 5.33
Cap/Depr 62.99%
Cap/Sales 5.85%
Interest Coverage 2.12
Cash Conversion 15.51%
Profit Quality N/A
Current Ratio 2.54
Quick Ratio 1.46
Altman-Z 1.21
F-Score4
WACC6.15%
ROIC/WACC0.71
Cap/Depr(3y)66.1%
Cap/Depr(5y)55.65%
Cap/Sales(3y)5.76%
Cap/Sales(5y)4.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.89%
EPS 3Y-12.69%
EPS 5Y-1.86%
EPS Q2Q%-14.43%
EPS Next Y7.41%
EPS Next 2Y8.27%
EPS Next 3Y7.61%
EPS Next 5YN/A
Revenue 1Y (TTM)1.53%
Revenue growth 3Y1.63%
Revenue growth 5Y3.57%
Sales Q2Q%-1.74%
Revenue Next Year2.65%
Revenue Next 2Y3.02%
Revenue Next 3Y3%
Revenue Next 5YN/A
EBIT growth 1Y-5.3%
EBIT growth 3Y-16.12%
EBIT growth 5Y-4.59%
EBIT Next Year20.58%
EBIT Next 3Y11.05%
EBIT Next 5YN/A
FCF growth 1Y-401.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.06%
OCF growth 3Y-42.46%
OCF growth 5Y-24.38%

INTEGRA LIFESCIENCES HOLDING / IART Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for INTEGRA LIFESCIENCES HOLDING?

ChartMill assigns a fundamental rating of 3 / 10 to IART.


What is the valuation status for IART stock?

ChartMill assigns a valuation rating of 7 / 10 to INTEGRA LIFESCIENCES HOLDING (IART). This can be considered as Undervalued.


Can you provide the profitability details for INTEGRA LIFESCIENCES HOLDING?

INTEGRA LIFESCIENCES HOLDING (IART) has a profitability rating of 3 / 10.


Can you provide the financial health for IART stock?

The financial health rating of INTEGRA LIFESCIENCES HOLDING (IART) is 2 / 10.


Can you provide the expected EPS growth for IART stock?

The Earnings per Share (EPS) of INTEGRA LIFESCIENCES HOLDING (IART) is expected to grow by 7.41% in the next year.